8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid | 1147752-30-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid
• 英文别名: 8-[Benzyl-[1-oxo-1-(2-phenylethylamino)-3-(4-phenylphenyl)propan-2-yl]amino]-8-oxooctanoic acid
• CAS: 1147752-30-4
• 化学式: C₃₈H₄₂N₂O₄
• 分子量: 590.762
• InChiKey: BLYHOMJJGXNDII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid 、 O-(叔丁基二甲基硅烷)羟胺 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases

  摘要：

  HDAC inhibitors show great promise for the treatment of cancer. AS part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SARA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the alpha-aminoacylamides can be favorable in the interaction with the enzyme.

  DOI：

  10.1021/jm801529c
• 作为产物：
  描述：

  8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid ethyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以99%的产率得到8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases

  摘要：

  HDAC inhibitors show great promise for the treatment of cancer. AS part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SARA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the alpha-aminoacylamides can be favorable in the interaction with the enzyme.

  DOI：

  10.1021/jm801529c

文献信息

• Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases
  作者：Ambra A. Grolla、Valeria Podestà、Maria Giovanna Chini、Simone Di Micco、Antonella Vallario、Armando A. Genazzani、Pier Luigi Canonico、Giuseppe Bifulco、Gian Cesare Tron、Giovanni Sorba、Tracey Pirali

  DOI：10.1021/jm801529c

  日期：2009.5.14

  HDAC inhibitors show great promise for the treatment of cancer. AS part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SARA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the alpha-aminoacylamides can be favorable in the interaction with the enzyme.